Fermenta Biotech surges on getting nod to raise Rs 150 crore
Fermenta Biotech is currently trading at Rs 308.90, up by 8.35 points or 2.78% from its previous closing of Rs 300.55 on the BSE.
The scrip opened at Rs 298.00 and has touched a high and low of Rs 310.00 and Rs 294.10 respectively. So far 22855 shares were traded on the counter.
The BSE group 'X' stock of face value Rs 5 has touched a 52-week high of Rs 449.00 on 11-Feb-2025 and a 52-week low of Rs 219.00 on 28-Feb-2025.
Last one week high and low of the scrip stood at Rs 310.00 and Rs 256.40 respectively. The current market cap of the company is Rs 909.12 crore.
The promoters holding in the company stood at 64.09%, while Institutions and Non-Institutions held 0.02% and 35.89% respectively.
Fermenta Biotech has received approval for raising of funds either by way of issuance of equity shares and/or other securities including securities convertible into equity shares, warrants or fully convertible debentures, partly convertible debentures, non-convertible debentures along with warrants, or convertible preference shares (collectively ‘Securities’), for an aggregate amount not exceeding Rs 150 crore, by way of public issue, rights issue, preferential allotment, private placement, including Qualified Institutions Placement(s) (QIP) in one or more tranches or any other mode or combination thereof as may be permitted under applicable laws, such regulatory/statutory approvals as may be required, and subject to approval of shareholders of the Company, which will be sought separately at the appropriate time. The Board of Directors of the Company, at its meeting held on December 10, 2025, has, inter alia, considered and approved the same.
Fermenta Biotech possesses a growing portfolio of nutrition including customized Premixes, Fortified Rice Kernel (FRK) and other nutritional ingredients. Apart from its nutrition portfolio, the company is one of the world’s leading manufacturers of Vitamin D3.
